TW201014855A - Compounds for the treatment of hepatitis C - Google Patents

Compounds for the treatment of hepatitis C Download PDF

Info

Publication number
TW201014855A
TW201014855A TW098130826A TW98130826A TW201014855A TW 201014855 A TW201014855 A TW 201014855A TW 098130826 A TW098130826 A TW 098130826A TW 98130826 A TW98130826 A TW 98130826A TW 201014855 A TW201014855 A TW 201014855A
Authority
TW
Taiwan
Prior art keywords
group
solvent
phenyl
alkyl
minutes
Prior art date
Application number
TW098130826A
Other languages
English (en)
Chinese (zh)
Inventor
Richard Pracitto
John F Kadow
John A Bender
Brett R Beno
Katharine A Grant-Young
Ying Han
Piyasena Hewawasam
Andrew Nickel
Kyle E Parcella
Kap-Sun Yeung
Louis S Chupak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW201014855A publication Critical patent/TW201014855A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW098130826A 2008-09-11 2009-09-11 Compounds for the treatment of hepatitis C TW201014855A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9600408P 2008-09-11 2008-09-11
US12/549,983 US8198449B2 (en) 2008-09-11 2009-08-28 Compounds for the treatment of hepatitis C

Publications (1)

Publication Number Publication Date
TW201014855A true TW201014855A (en) 2010-04-16

Family

ID=41203516

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098130826A TW201014855A (en) 2008-09-11 2009-09-11 Compounds for the treatment of hepatitis C

Country Status (10)

Country Link
US (2) US8198449B2 (enExample)
EP (1) EP2331502B1 (enExample)
JP (1) JP2012502099A (enExample)
KR (1) KR20110056537A (enExample)
CN (2) CN102209711B (enExample)
AR (1) AR073586A1 (enExample)
AU (1) AU2009291993A1 (enExample)
MX (1) MX2011002471A (enExample)
TW (1) TW201014855A (enExample)
WO (1) WO2010030538A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用
IN2012DN04917A (enExample) * 2009-11-05 2015-09-25 Univ Notre Dame Du Lac
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
US8324212B2 (en) * 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011112186A1 (en) * 2010-03-10 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2630128A4 (en) * 2010-10-20 2013-08-28 Biota Scient Management VIRUS POLYMERASE INHIBITORS
EA025151B1 (ru) 2010-10-26 2016-11-30 Пресидио Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013148620A1 (en) 2012-03-27 2013-10-03 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
US9365554B2 (en) 2012-04-11 2016-06-14 Aviragen Therapeutics, Inc. Viral polymerase inhibitors
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
CN102690264B (zh) * 2012-06-20 2014-07-02 泰山医学院 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法
HK1206250A1 (en) 2012-06-26 2016-01-08 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
BR112015000459B1 (pt) 2012-07-09 2022-02-08 Janssen Pharmaceutica N.V. Inibidores da enzima fosfodiesterase 10, seu uso, composição farmacêutica que os compreende, seus processo de preparação e produto
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9624214B2 (en) * 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
ME03042B (me) 2012-11-19 2018-10-20 Novartis Ag Jedinjenja i kompozicije za tretman parazitskih oboljenja
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US8962651B2 (en) * 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2625744T3 (es) 2013-06-04 2017-07-20 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso
TW201609651A (zh) * 2013-11-12 2016-03-16 陶氏農業科學公司 用於氟化化合物之過程(一)
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト 3−(ピリミジン−2−イル)イミダゾ[1,2−a]ピリジン
TW201620914A (zh) * 2014-03-21 2016-06-16 必治妥美雅史谷比公司 含有氰基之氮雜苯并呋喃化合物用於治療c型肝炎
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
EP3119769A1 (en) * 2014-03-21 2017-01-25 Bristol-Myers Squibb Pharma Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
US20170057958A1 (en) 2014-05-02 2017-03-02 Bayer Pharma Aktiengesellschaft Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
WO2016022513A1 (en) * 2014-08-05 2016-02-11 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis c
US10100027B2 (en) 2014-09-26 2018-10-16 Changzhou Yinsheng Pharmaceutical Co., Ltd. Benzofuran analogue as NS4B inhibitor
US10292970B2 (en) 2014-12-02 2019-05-21 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
US10919888B2 (en) 2015-09-17 2021-02-16 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
RU2019123849A (ru) 2019-07-29 2021-02-01 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Ингибиторы фактора ингибирования миграции макрофагов
WO2024102699A1 (en) * 2022-11-07 2024-05-16 ELANCO US, Inc. Guanylate cyclase (gc) stimulator formulations and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502707A (en) * 1967-09-11 1970-03-24 Mcneilab Inc Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
DE59303357D1 (de) * 1992-10-29 1996-09-05 Hoechst Ag Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen
DK0924209T3 (da) * 1997-12-19 2003-08-25 Lilly Co Eli Hypoglykæmiske imidazolinforbindelser
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1372642A1 (en) 2001-03-30 2004-01-02 SmithKline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
WO2003097062A1 (en) 2002-05-13 2003-11-27 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
KR20050065661A (ko) * 2002-11-01 2005-06-29 비로파마 인코포레이티드 벤조푸란 화합물, 조성물 및 c형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법
TW200528459A (en) * 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
CA2672960A1 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
MX2009008439A (es) * 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
JP2008247878A (ja) 2007-03-30 2008-10-16 Maruishi Pharmaceutical Co Ltd イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
MX2010004623A (es) 2008-02-14 2010-06-07 Hoffmann La Roche Compuestos heterociclicos antiviricos.
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
WO2010030538A2 (en) 2010-03-18
MX2011002471A (es) 2011-04-05
EP2331502B1 (en) 2016-03-02
AR073586A1 (es) 2010-11-17
EP2331502A2 (en) 2011-06-15
CN102209711A (zh) 2011-10-05
US20120232099A1 (en) 2012-09-13
CN102209711B (zh) 2014-06-18
KR20110056537A (ko) 2011-05-30
JP2012502099A (ja) 2012-01-26
WO2010030538A3 (en) 2010-05-06
CN103864783A (zh) 2014-06-18
AU2009291993A1 (en) 2010-03-18
US20100063068A1 (en) 2010-03-11
US8198449B2 (en) 2012-06-12
US8536338B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
TW201014855A (en) Compounds for the treatment of hepatitis C
JP5572725B2 (ja) C型肝炎の処置のための化合物
US8293909B2 (en) Compounds for the treatment of hepatitis C
CN109153642B (zh) 赖氨酰氧化酶的吲哚及氮杂吲哚卤化烯丙胺衍生物抑制剂及其用途
CN114302886B (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN101821268B (zh) 用于治疗丙型肝炎的四环化合物
CN106661056B (zh) 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物
CN112409385B (zh) 氮杂芳基化合物及其应用
EP2953456A1 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN102892767A (zh) 治疗丙型肝炎的化合物
CN105884779A (zh) 作为丙型肝炎抑制剂的化合物及其在药物中的应用
CN112300154B (zh) 一类含氮杂环化合物、其制备方法和用途
CN107406435A (zh) 新的治疗丙型肝炎的化合物
TW201011030A (en) Tricyclic indole derivatives and methods of use thereof
KR20130008570A (ko) C형 간염의 치료를 위한 피라졸로피리다진 유도체
EP2953461B1 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN118420607A (zh) 杂芳环化合物及其应用
HK40066114B (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
HK40066114A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
TW201444828A (zh) 可作爲溴區結構域蛋白抑制劑之咔唑化合物